A clinical study of long-term administration of dextran sulfate (MDS Kowa) in patients with retinopathy.
We administered MDS at a daily dose of 1,800 mg to 25 patients with diabetic retinopathy for periods ranging from 12 to 48 months (mean: 28 months) and achieved the following results: 1) During the administration period total cholesterol, triglyceride and fibrinogen levels were all maintained at significantly lower levels. 2) Eye fundus findings showed an improvement in 38.9% no change in 47. 2% and a deterioration in 13.9% of the cases. 3) No side-effects or abnormalities in clinical findings were observed in any of the cases even though clinical tests of hepatic function, renal function, blood chemistry, and urinalysis were conducted. The above results demonstrate that MDS has a marked effect on diabetic retinopathy, especially in cases with moderate to severe symptoms during the non-proliferative stage.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D016264:Dextran Sulfate; D003911:Dextrans / Q000008:administration & dosage / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D003911:Dextrans; D014280:Triglycerides; D005340:Fibrinogen; D016264:Dextran Sulfate; D002784:Cholesterol